Abstract
The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Reviews on Recent Clinical Trials
Title:Gut Microbiota and Alcoholic Liver Disease
Volume: 11 Issue: 3
Author(s): Emidio Scarpellini, Mariana Forlino, Marinella Lupo, Carlo Rasetti, Giammarco Fava, Ludovico Abenavoli and Adriano De Santis
Affiliation:
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Abstract: The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Export Options
About this article
Cite this article as:
Scarpellini Emidio, Forlino Mariana, Lupo Marinella, Rasetti Carlo, Fava Giammarco, Abenavoli Ludovico and De Santis Adriano, Gut Microbiota and Alcoholic Liver Disease, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160810100538
DOI https://dx.doi.org/10.2174/1574887111666160810100538 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding Genetic Factors in Idiopathic Scoliosis, a Complex Disease of Childhood
Current Genomics Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy The Role of Angiogenesis as a Prognostic Factor of Breast Cancer: Recent Review
Current Women`s Health Reviews The PYRIN Domain in Signal Transduction
Current Protein & Peptide Science Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) The Therapeutic Potential of ADAM15
Current Pharmaceutical Design T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Abundance and Diversity of GI Microbiota Rather than IgG<sub>4</sub> Levels Correlate with Abdominal Inconvenience and Gut Permeability in Consumers Claiming Food Intolerances
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology